Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SENS Stock Forecast 2025-2026
$0.63
Current Price
$408.93M
Market Cap
Buy 3
Hold 1
Sell 1
Wall St Analyst Ratings
Distance to SENS Price Targets
+298.3%
To High Target of $2.50
+218.6%
To Median Target of $2.00
+218.6%
To Low Target of $2.00
SENS Price Momentum
-6.0%
1 Week Change
+5.0%
1 Month Change
+34.0%
1 Year Change
+21.2%
Year-to-Date Change
-55.2%
From 52W High of $1.40
+151.1%
From 52W Low of $0.25
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Senseonics (SENS) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on SENS and similar high-potential opportunities.
Latest SENS Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, SENS has a bullish consensus with a median price target of $2.00 (ranging from $2.00 to $2.50). The overall analyst rating is Buy (7.6/10). Currently trading at $0.63, the median forecast implies a 218.6% upside. This outlook is supported by 3 Buy, 1 Hold, and 1 Sell ratings.
Conversely, the most conservative target is provided by Anthony Petrone at Mizuho, suggesting a 218.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SENS Analyst Ratings
3
Buy
1
Hold
1
Sell
SENS Price Target Range
Low
$2.00
Average
$2.00
High
$2.50
Current: $0.63
Latest SENS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SENS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 10, 2025 | Mizuho | Anthony Petrone | Outperform | Initiates | $2.00 |
| Mar 5, 2025 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $2.00 |
| Nov 15, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $2.00 |
| Aug 14, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $2.00 |
| Mar 11, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $2.00 |
| Nov 14, 2023 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $2.00 |
| Aug 15, 2023 | HC Wainwright & Co. | Vernon Bernardino | Buy | Maintains | $2.00 |
| Jul 19, 2023 | Jefferies | Matthew Taylor | Underperform | Initiates | $0.50 |
| May 11, 2023 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $3.00 |
| Jul 25, 2022 | HC Wainwright & Co. | Vernon Bernardino | Buy | Maintains | $3.00 |
| Aug 19, 2021 | HC Wainwright & Co. | Buy | Initiates | $0.00 | |
| Apr 1, 2021 | SVB Leerink | Market Perform | Downgrade | $0.00 | |
| Mar 5, 2021 | Raymond James | Underperform | Downgrade | $0.00 | |
| Mar 5, 2021 | SVB Leerink | Danielle Antalffy | Outperform | Maintains | $3.00 |
| Jan 21, 2021 | BTIG | Neutral | Downgrade | $0.00 | |
| Jan 20, 2021 | Craig-Hallum | Sell | Downgrade | $0.00 | |
| Aug 11, 2020 | Craig-Hallum | Hold | Upgrade | $0.00 | |
| Aug 11, 2020 | BTIG | Buy | Upgrade | $0.00 | |
| Jun 10, 2020 | Stifel | Buy | Maintains | $1.00 | |
| Jun 10, 2020 | SVB Leerink | Outperform | Maintains | $1.00 |
Senseonics Holdings Inc. (SENS) Competitors
The following stocks are similar to Senseonics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Senseonics Holdings Inc. (SENS) Financial Data
Senseonics Holdings Inc. has a market capitalization of $408.93M with a P/E ratio of -5.2x. The company generates $22.47M in trailing twelve-month revenue with a 2.4% profit margin.
Revenue growth is +3.3% quarter-over-quarter, while maintaining an operating margin of -172.0% and return on equity of -166.3%.
Valuation Metrics
Market Cap
$408.93M
Enterprise Value
$504.40M
P/E Ratio
-5.2x
PEG Ratio
-5.2x
Price/Sales
18.2x
Growth & Margins
Revenue Growth (YoY)
+3.3%
Gross Margin
+47.6%
Operating Margin
-172.0%
Net Margin
+2.4%
EPS Growth
+3.3%
Financial Health
Cash/Price Ratio
+18.2%
Current Ratio
2.4x
Debt/Equity
289.3x
ROE
-166.3%
ROA
-39.2%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Senseonics Holdings Inc. (SENS) Business Model
About Senseonics Holdings Inc.
What They Do
Develops long-term implantable glucose monitoring systems.
Business Model
Senseonics Holdings generates revenue through the design, development, and commercialization of its Eversense continuous glucose monitoring (CGM) systems. The company markets its innovative CGM products to healthcare providers and distributors, emphasizing the advantages of fewer sensor replacements and improved diabetes management for patients.
Additional Information
Headquartered in Germantown, Maryland, Senseonics collaborates with healthcare professionals globally to enhance diabetes care. Their focus on long-term solutions positions them favorably in the healthcare technology sector, addressing the needs of individuals with diabetes and improving patient compliance.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
117
CEO
Dr. Timothy T. Goodnow Ph.D.
Country
United States
IPO Year
2015
Website
www.senseonics.comSenseonics Holdings Inc. (SENS) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Senseonics Holdings (SENS) Reports Q1 Loss, Tops Revenue Estimates
Senseonics (SENS) delivered earnings and revenue surprises of 0% and 16.84%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
May 08, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Senseonics Holdings, Inc. will hold its Q1 2025 Earnings Conference Call on May 8, 2025, at 4:30 PM ET, featuring key executives and investor relations representatives.
Why It Matters
The upcoming earnings call for Senseonics on May 8, 2025, will provide insights into the company's financial performance and future outlook, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Senseonics Holdings (SENS) reported a quarterly loss of $0.02 per share, matching analyst expectations and improving from a loss of $0.03 per share in the same quarter last year.
Why It Matters
Senseonics’ quarterly loss aligns with expectations, indicating stability. The improved year-over-year performance may signal potential for future growth, influencing investor sentiment positively.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Senseonics Holdings, Inc. (SENS) will release its Q1 2025 financial results on May 8, 2025, after market close. The company focuses on long-term implantable CGM systems for diabetes.
Why It Matters
Senseonics' upcoming earnings report could signal financial health and growth prospects, impacting stock performance and investor confidence in the diabetes management sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Twiist™ is now the first AID system compatible with Senseonics Eversense® 365 one-year CGM system, expanding its market offerings.
Why It Matters
The expansion of twiist™ compatibility with Senseonics Eversense® 365 enhances its market position, potentially increasing sales and attracting more partnerships in the growing CGM sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Senseonics (SENS) has been upgraded to a Zacks Rank #2 (Buy), indicating increased optimism about its earnings, which may lead to a potential rise in the stock price.
Why It Matters
Senseonics' upgrade to a Zacks Rank #2 indicates improved earnings outlook, potentially leading to higher stock prices and increased investor interest.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Senseonics Holdings, Inc. (NYSE:SENS) will hold its Q4 2024 earnings conference call on March 3, 2025, at 4:30 PM ET, featuring key executives and financial analysts.
Why It Matters
The earnings call signals upcoming financial insights and strategic direction for Senseonics, impacting investor sentiment and stock performance. Key participants' insights can influence market perception.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About SENS Stock
What is Senseonics Holdings Inc.'s (SENS) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, Senseonics Holdings Inc. (SENS) has a median price target of $2.00. The highest price target is $2.50 and the lowest is $2.00.
Is SENS stock a good investment in 2025?
According to current analyst ratings, SENS has 3 Buy ratings, 1 Hold ratings, and 1 Sell ratings. The stock is currently trading at $0.63. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SENS stock?
Wall Street analysts predict SENS stock could reach $2.00 in the next 12 months. This represents a 218.6% increase from the current price of $0.63. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Senseonics Holdings Inc.'s business model?
Senseonics Holdings generates revenue through the design, development, and commercialization of its Eversense continuous glucose monitoring (CGM) systems. The company markets its innovative CGM products to healthcare providers and distributors, emphasizing the advantages of fewer sensor replacements and improved diabetes management for patients.
What is the highest forecasted price for SENS Senseonics Holdings Inc.?
The highest price target for SENS is $2.50 from at , which represents a 298.3% increase from the current price of $0.63.
What is the lowest forecasted price for SENS Senseonics Holdings Inc.?
The lowest price target for SENS is $2.00 from Anthony Petrone at Mizuho, which represents a 218.6% increase from the current price of $0.63.
What is the overall SENS consensus from analysts for Senseonics Holdings Inc.?
The overall analyst consensus for SENS is bullish. Out of 6 Wall Street analysts, 3 rate it as Buy, 1 as Hold, and 1 as Sell, with a median price target of $2.00.
How accurate are SENS stock price projections?
Stock price projections, including those for Senseonics Holdings Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 11, 2025 5:30 PM UTC